Published Aug 26, 2021

Jeff Hammerbacher — From data science to biomedicine

Jeff Hammerbacher shares his transformative journey from pioneering data science at Facebook, co-founding Cloudera, to revolutionizing biomedicine with innovative approaches in cancer therapy at Related Sciences, showcasing his commitment to harnessing data for groundbreaking advancements.
Episode Highlights
Gradient Dissent - A Machine Learning Podcast logo

Popular Clips

Episode Highlights

  • Company Origins

    The founding of Cloudera was a collaborative effort driven by the need for advanced data management tools. and Christoph Michelia initiated the idea in 2008, motivated by the potential acquisition of Yahoo by Microsoft, which accelerated their timeline 1. They were joined by Mike Olsen and Amar Awadala1. Jeff reflects on his career transition, noting his desire to apply data science in a field with more engaging subject matter, leading him eventually to biomedicine 2.

    I really enjoyed my jobs. I just could not care less about what the product was at each of those jobs.

    ---

    This transition was driven by a search for a domain where he wouldn't tire of the entities under analysis, ultimately finding biomedicine to be a field ripe with opportunity and in need of modern technical infrastructure.

       

    Market Strategy

    Cloudera's market strategy was shaped by the evolving needs of the data industry and the challenges of pricing models. Jeff admired Splunk's consumption-based pricing but found Cloudera stuck with a more traditional model akin to Oracle or Teradata 3. Despite these challenges, the vision was to create a vertically integrated data platform, akin to what companies like Snowflake and Databricks aim for today 3. Fundraising was a significant hurdle, with skepticism about the market size and potential for large-scale adoption 4.

    I didn't expect it to get as big as it did, or people to care as much as they did.

    ---

    Jeff's focus was on building open-source infrastructure to democratize data capabilities, rather than purely commercial success, which was reflected in the modest initial funding rounds.

Related Episodes